299 related articles for article (PubMed ID: 37731164)
21. Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Hui VW; Au CL; Lam ASM; Yip TC; Tse YK; Lai JC; Chan HL; Wong VW; Wong GL
Hepatol Int; 2022 Dec; 16(6):1318-1329. PubMed ID: 36074319
[TBL] [Abstract][Full Text] [Related]
22. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.
Spengler U
Pharmacol Ther; 2018 Mar; 183():118-126. PubMed ID: 29024739
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Risk Management and Hepatitis C: Combining Drugs.
Smolders EJ; Ter Horst PJG; Wolters S; Burger DM
Clin Pharmacokinet; 2019 May; 58(5):565-592. PubMed ID: 30259390
[TBL] [Abstract][Full Text] [Related]
25. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical Approaches for Treatment of Hepatitis C virus.
Milani A; Basimi P; Agi E; Bolhassani A
Curr Pharm Des; 2020; 26(34):4304-4314. PubMed ID: 32386486
[TBL] [Abstract][Full Text] [Related]
27. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
Maasoumy B; Port K; Calle Serrano B; Markova AA; Sollik L; Manns MP; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1365-72. PubMed ID: 24127648
[TBL] [Abstract][Full Text] [Related]
28. Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Smolders EJ; Smit C; T M M de Kanter C; Dofferiiof ASM; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):193-199. PubMed ID: 28902678
[TBL] [Abstract][Full Text] [Related]
29. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; MartÃnez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
30. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
31. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
[TBL] [Abstract][Full Text] [Related]
32. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals.
Cope R; Pickering A; Glowa T; Faulds S; Veldkamp P; Prasad R
AIDS Patient Care STDS; 2015 Jul; 29(7):379-83. PubMed ID: 26066094
[TBL] [Abstract][Full Text] [Related]
33. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.
Furihata T; Matsumoto S; Fu Z; Tsubota A; Sun Y; Matsumoto S; Kobayashi K; Chiba K
Antimicrob Agents Chemother; 2014 Aug; 58(8):4555-64. PubMed ID: 24867984
[TBL] [Abstract][Full Text] [Related]
34. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.
Ottman AA; Townsend ML; Hashem MG; DiMondi VP; Britt RB
Ann Pharmacother; 2018 Aug; 52(8):763-768. PubMed ID: 29577765
[TBL] [Abstract][Full Text] [Related]
35. Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.
Bruno R; Cima S; Maiocchi L; Sacchi P
Dig Liver Dis; 2011 May; 43(5):337-44. PubMed ID: 20980211
[TBL] [Abstract][Full Text] [Related]
36. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
Meemken L; Hanhoff N; Tseng A; Christensen S; Gillessen A
Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
[TBL] [Abstract][Full Text] [Related]
37. Psychiatric treatment considerations with direct acting antivirals in hepatitis C.
Sockalingam S; Tseng A; Giguere P; Wong D
BMC Gastroenterol; 2013 May; 13():86. PubMed ID: 23672254
[TBL] [Abstract][Full Text] [Related]
38. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
40. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
